[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 3420 Introduced in Senate (IS)]

<DOC>






115th CONGRESS
  2d Session
                                S. 3420

     To require the Food and Drug Administration to prioritize the 
promotional materials for drugs for serious, life-threatening diseases 
 or conditions or substance use disorders, especially opioid drugs and 
    drugs for medication-assisted treatment, in considering whether 
             promotional materials are false or misleading.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           September 6, 2018

Ms. Harris (for herself and Mr. Gardner) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
     To require the Food and Drug Administration to prioritize the 
promotional materials for drugs for serious, life-threatening diseases 
 or conditions or substance use disorders, especially opioid drugs and 
    drugs for medication-assisted treatment, in considering whether 
             promotional materials are false or misleading.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Accountability in Opioid Advertising 
Act''.

SEC. 2. PROMOTIONAL MATERIALS FOR DRUGS.

    In enforcing section 303(g) of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 333(g)) and otherwise ensuring that advertising and 
other promotional materials for drugs approved under section 505 of 
such Act (21 U.S.C. 355), including pursuant to section 503C of such 
Act (21 U.S.C. 353c), are not false or misleading, the Secretary of 
Health and Human Services shall give priority consideration to 
advertising and other promotional materials for drugs for serious, 
life-threatening diseases or conditions or substance use disorders, 
especially opioid drugs and drugs for medication-assisted treatment.
                                 <all>